Skip to main content

Peter Lio, MD

Clinical Assistant Professor of Dermatology and Pediatrics
Feinberg School of Medicine
Northwestern University
Chicago, Illinois

Why is it important to parse out clinical phenotypes among pediatric and adult populations with atopic dermatitis? What is the importance of identifying clinical signatures and how can this impact therapeutic response and tolerability to therapies?

Why is it important to parse out clinical phenotypes among pediatric and adult populations with atopic dermatitis? What is the importance of identifying clinical signatures and how can this impact therapeutic response and tolerability to therapies?

The heterogeneity of atopic dermatitis in pediatric, adolescent, and adult populations is a critical feature of AD and, through precise identification of phenotypes and endotypes, can provide a therapy roadmap. Why is this important?

The heterogeneity of atopic dermatitis in pediatric, adolescent, and adult populations is a critical feature of AD and, through precise identification of phenotypes and endotypes, can provide a therapy roadmap. Why is this important?

Given the spectrum of therapeutic modalities for moderate-to-severe AD, can you provide a “therapeutic ladder” for how treatments, from corticosteroids to immunologically-based therapies should be sequenced in pediatric and adolescent patients?

Given the spectrum of therapeutic modalities for moderate-to-severe AD, can you provide a “therapeutic ladder” for how treatments, from corticosteroids to immunologically-based therapies should be sequenced in pediatric and adolescent patients?

Can you share a case where topical therapies have failed to produce an acceptable clinical response, and in whom consideration of immunotherapy—including systemic treatment with dupilumab—would be indicated?

Can you share a case where topical therapies have failed to produce an acceptable clinical response, and in whom consideration of immunotherapy—including systemic treatment with dupilumab—would be indicated?

Can you review the current evidentiary basis for the deployment of dupilumab in pediatric and adolescent age groups, and how clinical outcomes, time to resolution, and dosing consideration compare to results reported in the original trials in adults?

Can you review the current evidentiary basis for the deployment of dupilumab in pediatric and adolescent age groups, and how clinical outcomes, time to resolution, and dosing consideration compare to results reported in the original trials in adults?

With respect to dosing regimens and duration of therapy using dupilumab in the pediatric and adolescent age groups, what do the trials, FDA approval guidance, and your clinical experience suggest as practical roadmaps in this population?

With respect to dosing regimens and duration of therapy using dupilumab in the pediatric and adolescent age groups, what do the trials, FDA approval guidance, and your clinical experience suggest as practical roadmaps in this population?

Many dermatologists who observe and report excellent efficacy and tolerability with dupilumab also are asking: “How long should treatment be continued?” Can you provide guidance on this commonly asked question and on the safety profile?

With respect to dupilumab, what is the mechanistic relevance of targeting type 2 cytokine signaling systems—IL-4 and IL-13—and how does this translate into clinical effectiveness observed in clinical trials?

With respect to dupilumab, what is the mechanistic relevance of targeting type 2 cytokine signaling systems—IL-4 and IL-13—and how does this translate into clinical effectiveness observed in clinical trials?

In the dupilumab trials, do patients treated with this agent respond predictably in terms of amelioration of specific symptoms—itch, redness, appearance—and how long does it take to see treatment response?

In the dupilumab trials, do patients treated with this agent respond predictably in terms of amelioration of specific symptoms—itch, redness, appearance—and how long does it take to see treatment response?

In light of the significant unmet need for AD treatment in children between the ages of 2 and 12, and even younger what do the most recent clinical trials show about the safety and efficacy of dupilumab in these young age groups?

In light of the significant unmet need for AD treatment in children between the ages of 2 and 12, and even younger what do the most recent clinical trials show about the safety and efficacy of dupilumab in these young age groups?

What the “therapeutic ladder” for AD in the pediatric and adolescent group, and what is the trigger for systemic immunotherapy? Where does dupilumab-mediated, type 2 cytokine-targeting fit into your approach to AD in the younger population?

What the “therapeutic ladder” for AD in the pediatric and adolescent group, and what is the trigger for systemic immunotherapy? Where does dupilumab-mediated, type 2 cytokine-targeting fit into your approach to AD in the younger population?